Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Trastornos del Movimiento
FILTRAR POR:
Por tema
4724 ARTÍCULOS , VIENDO DEL 466 AL 480
von Manitius S, Flügel D, Gievers Steinlein B, Schnelle M, von Mandach U, Simões-Wüst AP.
Clin Case Rep. 2019 Apr 14;7(5):1012-1020. doi: 10.1002/ccr3.2144. eCollection 2019 May.
Nasiri M, Abbasi M, Khosroabadi ZY, Saghafi H, Hamzeei F, Amiri MH, Yusefi H.
Complement Ther Med. 2019 Jun;44:261-268. doi: 10.1016/j.ctim.2019.05.009. Epub 2019 May 8.
Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review
Ahmed S, Bachu R, Kotapati P, Adnan M, Ahmed R, Farooq U, Saeed H, Khan AM, Zubair A, Qamar I, Begum G.
Front Psychiatry. 2019 May 7;10:228. doi: 10.3389/fpsyt.2019.00228. eCollection 2019.
Improvement of Restless Legs Syndrome Under Treatment of Cancer Pain With Morphine and Fentanyl
Gärtner J, Jaroslawski K, Becker G, Boehlke C.
Front Neurol. 2019 May 8;10:457. doi: 10.3389/fneur.2019.00457. eCollection 2019.
Restless legs syndrome is associated with arterial stiffness and clinical outcome in stroke patients
Han SH, Park KY, Kim JM, Youn YC, Shin HW.
Sleep Med. 2019 Aug;60:219-223. doi: 10.1016/j.sleep.2019.03.027. Epub 2019 Apr 20.
Brupbacher G, Straus D, Porschke H, Zander-Schellenberg T, Gerber M, von Känel R, Schmidt-Trucksäss A.
Trials. 2019 Jun 13;20(1):352. doi: 10.1186/s13063-019-3415-3.
Restless legs syndrome: Clinical changes in nervous system excitability at the spinal cord level
Dafkin C, McKinon W, Kerr S.
Sleep Med Rev. 2019 Oct;47:9-17. doi: 10.1016/j.smrv.2019.05.005. Epub 2019 May 31.
The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA
Lanza G, Ferri R.
Adv Pharmacol. 2019;84:101-119. doi: 10.1016/bs.apha.2018.12.002. Epub 2019 Jan 18.
Iron uptake at the blood-brain barrier is influenced by sex and genotype
Wade QW, Chiou B, Connor JR.
Adv Pharmacol. 2019;84:123-145. doi: 10.1016/bs.apha.2019.02.005. Epub 2019 Mar 22.
Caenorhabditis elegans and its applicability to studies on restless legs syndrome
Chen P, Ijomone OM, Lee KH, Aschner M.
Adv Pharmacol. 2019;84:147-174. doi: 10.1016/bs.apha.2018.12.003. Epub 2019 Mar 14.
Role of MEIS1 in restless legs syndrome: From GWAS to functional studies in mice
Salminen AV, Lam DD, Winkelmann J.
Adv Pharmacol. 2019;84:175-184. doi: 10.1016/bs.apha.2019.03.003. Epub 2019 Apr 9.
Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome
Wanner V, Garcia Malo C, Romero S, Cano-Pumarega I, García-Borreguero D.
Adv Pharmacol. 2019;84:187-205. doi: 10.1016/bs.apha.2019.02.003. Epub 2019 Mar 14.
Idiopathic restless legs syndrome treatment: Progress and pitfalls?
Ghorayeb I.
Adv Pharmacol. 2019;84:207-235. doi: 10.1016/bs.apha.2019.01.004. Epub 2019 Feb 12.
D3 receptor agonist efficacy in restless legs syndrome
Casoni F, Galbiati A, Ferini-Strambi L.
Adv Pharmacol. 2019;84:21-35. doi: 10.1016/bs.apha.2019.01.005. Epub 2019 Feb 12.
Pharmacological treatments of augmentation in restless legs syndrome patients
Trenkwalder C, Paulus W.
Adv Pharmacol. 2019;84:255-265. doi: 10.1016/bs.apha.2019.02.002. Epub 2019 Mar 20.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.